POY_1170x120_8-12-19

Rajiv Malik

Pfizer combines its off-patent drug business with Mylan

Pfizer combines its off-patent drug business with Mylan

NEW YORK— Pfizer and Mylan announced Monday a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of

Lupin and Mylan team up to commercialize Enbrel

Lupin and Mylan team up to commercialize Enbrel

MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH — Pharma major Lupin and Mylan announced that the two companies will partner to commercialize a biosimilar to Enbrel (etanercept). Through the partnership agreement, Mylan will commercialize Lupin’s proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia. Enbrel is a TNF-inhibitor indicated to

Mylan to acquire Cold-EEZE

Mylan to acquire Cold-EEZE

PITTSBURGH — Mylan N.V. plans to acquire the global rights to the Cold-EEZE over-the-counter cold remedy brand from ProPhase Labs Inc. Under the agreement, Mylan’s U.S. OTC subsidiary will buy substantially all of the assets and other rights relating to the Cold-EEZE brand. Financial terms weren’t disclosed. Cold-EEZE products sold in the U.S. market include

Mylan closes acquisition of Meda

Mylan closes acquisition of Meda

PITTSBURGH — Mylan N.V. has completed its $9.9 billion deal to acquire Sweden-based Meda AB. Mylan had received Federal Trade Commission clearance for the transaction in late July. The deal was announced in February. The combination of Mylan and Meda creates a leading pharmaceutical company with a strong portfolio of brand-name and generic drugs and

Mylan to acquire Renaissance topicals business

Mylan to acquire Renaissance topicals business

PITTSBURGH — Mylan N.V. has entered an agreement to buy the nonsterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings LLC for $950 million in cash. Mylan said Friday that the Renaissance business, which has about 1,200 employees and posted sales of $370 million in 2015, will bring 25 branded and generic topical products,

Mylan names GSK veteran as global OTC leader

Mylan names GSK veteran as global OTC leader

HERTFORDSHIRE, England, and PITTSBURGH — Mylan N.V. has tabbed GlaxoSmithKline Consumer Healthcare veteran Ranjan Ray Chaudhuri to serve as global commercial lead of Mylan’s over-the-counter business. Chaudhuri will report to Rajiv Malik, president of Mylan. “The opportunity to build upon Mylan’s one-of-a-kind global platform and contribute to the organization’s ongoing evolution is tremendously exciting to